|View printer-friendly version|
|Infinity Announces Closing of Public Offering and Exercise of Over-Allotment Option|
The securities described above were offered by Infinity pursuant to a
shelf registration statement that was previously filed with, and
declared effective by, the
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Infinity is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase, heat shock protein 90 and fatty acid amide hydrolase are evidence of its innovative approach to drug discovery and development.
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a difference
include, without limitation, risks and uncertainties relating to
Infinity’s business, which can be found under the caption “Risk Factors”
included in Infinity's quarterly report on Form 10-Q for the quarterly